Efficacy of Tocilizumab in Patients with a Moderate and Severe COVID-19: A Retrospective Single Center Cohort Study
Introduction: Interleukin-6 (IL-6) is the key cytokine in “cytokine release syndrome” and associated with the lung fibrosis. Tocilizumab (TCZ) reduces the negative effects of inflammation by blocking the binding of IL-6 to its receptor. Materials and Methods: This was a retrospective observational...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Publishing House
2021-01-01
|
| Series: | Mediterranean Journal of Infection, Microbes and Antimicrobials |
| Subjects: | |
| Online Access: | http://mjima.org/abstract.php?id=297 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849307503431516160 |
|---|---|
| author | Sibel BOLUKÇU Dilara KARAKUŞ Gülay OKAY Yasemin AKKOYUNLU Bilge SÜMBÜL Bülent DURDU Meliha Meriç KOÇ Turan ASLAN |
| author_facet | Sibel BOLUKÇU Dilara KARAKUŞ Gülay OKAY Yasemin AKKOYUNLU Bilge SÜMBÜL Bülent DURDU Meliha Meriç KOÇ Turan ASLAN |
| author_sort | Sibel BOLUKÇU |
| collection | DOAJ |
| description | Introduction: Interleukin-6 (IL-6) is the key cytokine in “cytokine release syndrome” and associated with the lung fibrosis. Tocilizumab (TCZ) reduces the negative effects of inflammation by blocking the binding of IL-6 to its receptor.
Materials and Methods: This was a retrospective observational cohort study. Patients with microbiologically-confirmed Severe acute respiratory syndrome-Coronavirus-2 infection who received TCZ and standard treatment for Coronavirus disease-2019 (COVID‐19) were evaluated in the study.
Results: A total of 64 severe and moderate COVID-19 cases were included in this study. The mean age of the patients was 57.8±13.9 years and 68.8% (n=44) of them were male, 54.7% (n=35) of them had a severe COVID-19 infection and 45.3% (n=29) of them received TCZ therapy. Standard treatment group and TCZ group were compared in terms of the mortality and clinical changes such as a fever response and need for oxygen support. Fever response was detected within the first day of the treatment in the TCZ group. Additionally, need for oxygen support was lower in the TCZ group, although the difference was not statistically significant. Admission to the intensive care unit and mortality were lower in the TCZ group.
Conclusion: Efficacy of TCZ should be assessed in randomized placebo-controlled trials in the early phase of COVID-19 patients. |
| format | Article |
| id | doaj-art-2a94e6b6edb64dc2a8cb31c35b810008 |
| institution | Kabale University |
| issn | 2147-673X |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Galenos Publishing House |
| record_format | Article |
| series | Mediterranean Journal of Infection, Microbes and Antimicrobials |
| spelling | doaj-art-2a94e6b6edb64dc2a8cb31c35b8100082025-08-20T03:54:43ZengGalenos Publishing HouseMediterranean Journal of Infection, Microbes and Antimicrobials2147-673X2021-01-0110110.4274/mjima.galenos.2021.2021.68Efficacy of Tocilizumab in Patients with a Moderate and Severe COVID-19: A Retrospective Single Center Cohort StudySibel BOLUKÇU0https://orcid.org/0000-0001-6475-3894Dilara KARAKUŞ1https://orcid.org/0000-0002-5948-9424Gülay OKAY2https://orcid.org/0000-0003-1616-2162Yasemin AKKOYUNLU3https://orcid.org/0000-0003-0972-0461Bilge SÜMBÜL4https://orcid.org/0000-0002-8768-3777Bülent DURDU5https://orcid.org/0000-0002-0244-4006Meliha Meriç KOÇ6https://orcid.org/0000-0002-0563-6900Turan ASLAN7https://orcid.org/0000-0001-8832-5528Yeditepe University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, İstanbul, TurkeyBezmialem Vakıf University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, İstanbul, TurkeyBezmialem Vakıf University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, İstanbul, TurkeyBezmialem Vakıf University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, İstanbul, TurkeyBezmialem Vakıf University Faculty of Medicine, Department of Microbiology and Clinical Microbiology, İstanbul, TurkeyBezmialem Vakıf University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, İstanbul, TurkeyBezmialem Vakıf University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, İstanbul, TurkeyBezmialem Vakıf University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, İstanbul, TurkeyIntroduction: Interleukin-6 (IL-6) is the key cytokine in “cytokine release syndrome” and associated with the lung fibrosis. Tocilizumab (TCZ) reduces the negative effects of inflammation by blocking the binding of IL-6 to its receptor. Materials and Methods: This was a retrospective observational cohort study. Patients with microbiologically-confirmed Severe acute respiratory syndrome-Coronavirus-2 infection who received TCZ and standard treatment for Coronavirus disease-2019 (COVID‐19) were evaluated in the study. Results: A total of 64 severe and moderate COVID-19 cases were included in this study. The mean age of the patients was 57.8±13.9 years and 68.8% (n=44) of them were male, 54.7% (n=35) of them had a severe COVID-19 infection and 45.3% (n=29) of them received TCZ therapy. Standard treatment group and TCZ group were compared in terms of the mortality and clinical changes such as a fever response and need for oxygen support. Fever response was detected within the first day of the treatment in the TCZ group. Additionally, need for oxygen support was lower in the TCZ group, although the difference was not statistically significant. Admission to the intensive care unit and mortality were lower in the TCZ group. Conclusion: Efficacy of TCZ should be assessed in randomized placebo-controlled trials in the early phase of COVID-19 patients.http://mjima.org/abstract.php?id=297tocilizumabil-6covid-19turkey |
| spellingShingle | Sibel BOLUKÇU Dilara KARAKUŞ Gülay OKAY Yasemin AKKOYUNLU Bilge SÜMBÜL Bülent DURDU Meliha Meriç KOÇ Turan ASLAN Efficacy of Tocilizumab in Patients with a Moderate and Severe COVID-19: A Retrospective Single Center Cohort Study Mediterranean Journal of Infection, Microbes and Antimicrobials tocilizumab il-6 covid-19 turkey |
| title | Efficacy of Tocilizumab in Patients with a Moderate and Severe COVID-19: A Retrospective Single Center Cohort Study |
| title_full | Efficacy of Tocilizumab in Patients with a Moderate and Severe COVID-19: A Retrospective Single Center Cohort Study |
| title_fullStr | Efficacy of Tocilizumab in Patients with a Moderate and Severe COVID-19: A Retrospective Single Center Cohort Study |
| title_full_unstemmed | Efficacy of Tocilizumab in Patients with a Moderate and Severe COVID-19: A Retrospective Single Center Cohort Study |
| title_short | Efficacy of Tocilizumab in Patients with a Moderate and Severe COVID-19: A Retrospective Single Center Cohort Study |
| title_sort | efficacy of tocilizumab in patients with a moderate and severe covid 19 a retrospective single center cohort study |
| topic | tocilizumab il-6 covid-19 turkey |
| url | http://mjima.org/abstract.php?id=297 |
| work_keys_str_mv | AT sibelbolukcu efficacyoftocilizumabinpatientswithamoderateandseverecovid19aretrospectivesinglecentercohortstudy AT dilarakarakus efficacyoftocilizumabinpatientswithamoderateandseverecovid19aretrospectivesinglecentercohortstudy AT gulayokay efficacyoftocilizumabinpatientswithamoderateandseverecovid19aretrospectivesinglecentercohortstudy AT yaseminakkoyunlu efficacyoftocilizumabinpatientswithamoderateandseverecovid19aretrospectivesinglecentercohortstudy AT bilgesumbul efficacyoftocilizumabinpatientswithamoderateandseverecovid19aretrospectivesinglecentercohortstudy AT bulentdurdu efficacyoftocilizumabinpatientswithamoderateandseverecovid19aretrospectivesinglecentercohortstudy AT melihamerickoc efficacyoftocilizumabinpatientswithamoderateandseverecovid19aretrospectivesinglecentercohortstudy AT turanaslan efficacyoftocilizumabinpatientswithamoderateandseverecovid19aretrospectivesinglecentercohortstudy |